<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="retraction" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1252183</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2023.1252183</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: Quercetin inhibits tumorigenesis of colorectal cancer through downregulation of hsa_circ_0006990</article-title>
<alt-title alt-title-type="left-running-head">Frontiers Editorial Office</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2023.1252183">10.3389/fphar.2023.1252183</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Frontiers Editorial Office</surname>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891/overview"/>
</contrib>
<uri xlink:href="https://loop.frontiersin.org/people/228891/overview"/>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Approved by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/29938/overview">Angelo A. Izzo</ext-link>, University of Naples Federico II, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Frontiers Editorial Office, <email>research.integrity@frontiersin.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>07</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1252183</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>07</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Frontiers Editorial Office.</copyright-statement>
<copyright-year>2023</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" journal-id="Front. Pharmacol." journal-id-type="nlm-ta" xlink:href="10.3389/fphar.2022.874696" ext-link-type="doi">A Retraction of the Original Research Article <article-title>Quercetin inhibits tumorigenesis of colorectal cancer through downregulation of hsa_circ_0006990</article-title> by Chen B, Wu L, Tang X, Wang T, Wang S, Yu H, Wan G, Xie M, Zhang R, Xiao H and Deng W (2022). Front. Pharmacol. 13:874696. doi: <object-id>10.3389/fphar.2022.874696</object-id>
</related-article>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Gastrointestinal and Hepatic Pharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Following publication, the authors contacted the Editorial Office to request the retraction of the cited article, stating that cell lines used in the article were contaminated by <italic>Mycoplasma</italic>. It was confirmed by the authors when they tried to repeat their experiments unsuccessfully. The findings and conclusions reported in the article are no longer supported by the data. An investigation was conducted in accordance with Frontiers&#x2019; policies that confirmed this; therefore, the article has been retracted.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.</p>
</body>
</article>